BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View

BioMarin Pharmaceutical Inc. (BMRN) reported adjusted earnings per share of 96 cents in second-quarter 2024, beating the Zacks Consensus Estimate of 57 cents. Quarterly earnings, which rose 78% year over year, were driven by higher sales that were partially offset by rising operating expenses. Total revenues were $712.0 million in the reported quarter, up 20% year over year on a reported basis and 25% on a constant-currency basis. Strong sales of Voxzogo drove this upside. The top line beat the Zacks Consen ...